Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
Small Cell Lung Cancer
The panel discussed advancements in the field, including results from a study of lurbinectedin plus atezolizumab for SCLC.
Dr. Sen explains how her team identified targetable genes that define immune suppression in small cell lung cancer.
Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ...
Phase 3 DeLLphi-304 Trial Shows Tarlatamab Significantly Improves OS, PFS in Previously Treated SCLC
Charles Rudin, MD, PhD, presented the data at the 2025 American Society of Clinical Oncology Annual Meeting.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
The phase 3 DeLLphi-304 trial of tarlatamab versus standard-of-care chemotherapy has met its primary end point.
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Study investigators say the combination "showed promising efficacy" in patients with relapsed small cell lung cancer.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The recommendation is based on results from the phase 3 ADRIATIC trial.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.